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Introduction
 
Over the last few years pharmacoeconomics has
triggered great interest in Russia among medical
authorities, insurance companies, investigators con-
ducting clinical trials, and physicians. This interest
is explained two ways. First, in Russia, as in the rest
of the world, healthcare expenditures are acceler-
ating, increasingly expensive new pharmaceutical
products are being developed, and “grey power”
is rising (i.e., the proportion of our population
aged over 60 years is growing). The second reason
is specific to Russia and involves our developing
pharmaceutical market, the under-financing of our
healthcare system, and to a certain extent irratio-
nal approaches to clinical practice. This article is
intended to give a brief overview of some of the
current issues in pharmacoeconomics in Russia.
 
Financing and Reimbursement in the
Healthcare System
 
Total healthcare expenditure in 1996 was 2.8% of
the gross domestic product (GDP), compared to
Western developed countries where this value var-
ies between 5% and 16%. Moreover, it should be
taken into account that the absolute values for the
GDP are significantly higher in developed coun-
tries. It is clear that financing of the Russian
healthcare system is insufficient.
Nowadays there are two main sources of fi-
nancing for the healthcare system in Russia: the
federal budget and the Fund of Compulsory Med-
ical Insurance (FCMI). The ratio of these two
sources significantly varies between regions. In
Smolensk Regional Hospital in 1997 the propor-
tions of state budget and FCMI applied to financ-
ing total healthcare were approximately equal,
while those applied to financing pharmaceuticals
were 22% and 78%, respectively. Private medical
care also exists in Russia, but its role within the
healthcare system has not yet been determined.
The Maxwell Stamp Company has recently ques-
tioned patients from three representative regions
of Russia (Tula, Pskov, Penza) about the propor-
tion of patient contribution to the reimbursement
of pharmaceuticals. It was revealed that patients
covered 72% of drug costs (Fig. 1) [1].
 
Legislation for Pricing of Medicines
 
The federal government of Russia currently regu-
lates pricing of medicines. The government orga-
nization, which directly purchases medicine from
manufacturers (foreign or domestic), determines
the base price. This base price depends on pur-
chase price, organizational costs (transportation,
taxes, custom duties, etc.), and market demand for
the medicine.
The next step in pricing of medicine occurs
within each administrative entity (regions, repub-
lics, etc.) of Russia. Each entity has its own spe-
cific legislative acts that determine the extent of
extra charges added to the base price. For in-
stance, in the Smolensk region extra charges ac-
count for 20% over the base price for wholesale
and 30%–40% for retail, whereas in the neigh-
boring Tula region, extra charges correlate with
the base price; the bigger the base price, the
smaller the extra charge.
 
Principal Sources of Supply of Medicines
 
Both domestic and foreign pharmaceutical prod-
ucts are available on the Russian market. The total
Russian pharmaceutical market grew by 25% in
1997 to $2.3 billion at ex-factory prices. The top
eight Russian pharmaceutical manufacturers in 1997
are shown below (Table 1). Pharmaceutical con-
sumption per capita in 1997 was $12.50 US, and
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public expenditure on pharmaceuticals was an av-
erage of $9.50 US per capita, ranging from $1.70
to $28.30 US depending on the region [2].
The market share of imported pharmaceuticals is
77% (Fig. 2) [3]. There is discrepancy in the alloca-
tion of imported pharmaceutical products in Russia.
The biggest share of imports goes to Moscow
(73.4%), but this does not mean that all products
remain in the capital. Some are distributed to other
regions of Russia by wholesalers. St. Petersburg
ranks second in position (5.8%), followed by the
provinces of Moscow (5.1%), Novosibirsk (2.8%),
Ekatirinburg (1.3%), and Samara (1.1%) [4].
According to the report, “Characterization of the
Russian Federation Market, from the Informational
Bank for Pharmaceutical Production and Consump-
tion,” cardiovascular drugs, non-steroidal anti-
inflamatory drugs (NSAIDs), gastrointestinal (GI)
agents, anti-infectives, respiratory products, and psy-
chotropics will remain the leading therapeutic catego-
ries until the year 2000 [5]. Over-the-counter (OTC)
products account for 25%–45% of the pharmaceuti-
cal market [6].
 
Registration of Medicines
 
The Federal Law on Medicine regulates the phar-
maceutical registration process. According to this
law the federal body of control for quality of med-
icines must register all production, sales, and use
of medicines in the Russian Federation.
The following categories are subject to state
registration: 1) new medicines; 2) new combina-
tions of previously registered medicines; 3) previ-
ously registered medicines in new doses or formu-
lations; 4) medicines which have been reproduced
(generics). It is unnecessary to register medicines
prepared in pharmacies in accordance with doc-
tors’ prescriptions.
State registration of a medicine takes no longer
than 6 months from the day an application is sub-
mitted to the federal body of control for quality of
medicines. For state registration of a medicine, an
applicant (the representative of a pharmaceutical
manufacturer or any other legal entity with a
mandate from a pharmaceutical manufacturer)
must submit, in addition to the application, the
following documents and information:
• instructions for use;
• confirmation of payment of the state registra-
tion fee;
• the legal address of the manufacturer;
• data about production;
• initial text of the pharmacopoeia article;
• the name, including its international non-pat-
ented name and scientific name in the Latin
language, and main synonyms;
• the brand name, if it has been registered as a
trademark in accordance with the legislation
of the Russian Federation on trademarks and
service marks;
• samples of the product;
• a list of components and their quantity;
• documents confirming registration outside
Russia;
• a certificate of quality;
• methods of quality control;
• results of preclinical studies;
• results of clinical studies.
At times, the federal body of control over the
quality of medicines may accelerate procedures;
Figure 1 Reimbursement of pharmaceuticals by patient,
state budget, and Fund of Compulsory Medical Insurance
(FCMI) [1].
Table 1 Top Russian pharmaceutical companies in 1997 [2]
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Bryntsalov 177.3
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227.4 14.2
Moskhimfarmpreparaty 75.3
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17.1 6.0
Biosynthez 74.4
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20.6 5.9
Biokhimik 71.1
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9.9 5.7
Akrikhin 63.9
 

 
48.5 5.1
Synthez 61.8
 

 
17.6 4.9
ICN Oktyabr 59.5
 

 
44.0 4.7
ICN Leksredstva 44.0
 

 
44.3 3.5
Figure 2 Domestic and import distribution (%) of pharma-
ceutical products in the Russian market [3].
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however, this does not mean less stringent require-
ments for the quality, effectiveness, and safety of
medicines. The accelerated procedure may be ap-
plied if a reproduced medicine has been registered
to be equivalent to the original product already
registered in the Russian Federation and will be
reproduced in accordance with a previously ap-
proved technology and formulation. Once a medi-
cine has successfully completed the registration
process it is included in the state register of medi-
cines.
 
Opportunities for Training and Education
in Pharmacoeconomics
 
At present there is a lack of opportunity in Russia
for training or education in pharmacoeconomics.
Many erroneous conceptions about pharmacoeco-
nomics are common: pharmacoeconomics is simply
comparison of costs of drug treatments; pharmaco-
economics is theoretical only and not applicable to
clinical settings; foreign pharmacoeconomic studies
are sufficient—it is not necessary to conduct phar-
macoeconomic investigation in domestic clinical
settings.
Professionals working with pharmacoeconom-
ics look forward to changes in the near future.
They are relying on the organization of the Rus-
sian Chapter of the International Society for Phar-
macoeconomics and Outcomes Research (ISPOR).
Thanks to support from the Russian office of
Rhone-Poulenc Rorer, the founding meeting of es-
tablishment was held on October 29, 1998 in
Moscow. There were 10 participants at this meet-
ing, and the preliminary mission of the Russian
Chapter of ISPOR was defined to be:
 
• to distribute information about pharmacoeco-
nomics to interested parties (investigators, phy-
sicians, medical authorities, etc.);
• to provide training courses in pharmacoeco-
nomics;
• to promote the conduct of pharmacoeconomic
investigation in Russia;
• to translate into Russian and publish (with
ISPOR’s permission) ISPOR’s document con-
cerning Issues in Pharmacoeconomics.
In summary, pharmacoeconomics in Russia is
taking its first steps. Initially, attention will be fo-
cused on educational programs, dissemination of in-
formation, and explanation of the practical value
this science adds to medical authorities. The rich
methodological experience of the West will be a
valuable source for Russian investigators. However,
we are committed to the gathering of reliable phar-
macoeconomic data in Russian clinical settings.
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